The USFDA has approved Lupin Pharmaceuticals, Inc.’s application for Suprax® (Cefixime for oral suspension 200mg/5ml).
The new formulation is an extension of Lupin's flagship anti-infective brand Suprax® (Cefixime for oral suspension 100mg/5ml), a higher concentration formulation that will enable parents to administer fewer teaspoons per dose of the antibiotic to their children.
(When using the novel dose, parents would need to administer only half the volume of the existing 100mg/5ml suspension.)
According to Vinita Gupta, President, Lupin Pharmaceuticals, Inc.:
"The approval of our Cefixime for oral suspension 200mg/5ml product allows us to increase our share of the cephalosporin oral suspension pediatric market. This market is currently valued at $625 Million (as per IMS, Dec 2006). The incidence of respiratory infections is high in children and physicians need products that offer greater patient convenience and compliance."
Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited (BOM: 500257) – headquartered in Mumbai and is among the top five Pharmaceutical companies in India.
Read the full report.
Comment Preview